Development of metabolic syndrome at a young age as a manifestation of familial partial lipodystrophy type 3 (PPARG mutation): the first description of its clinical case in Russia

Metabolic syndrome (MS) is extremely common (20%–25% of the world’s population), and its diagnostic criteria are defined and well known. It has been shown that patients who have MS are twice as likely to die from a cardiovascular complication and three times as likely to suffer from it compared with patients without MS. However, the underlying cause of MS remains to be clearly elucidated, although inherited factors, such as insulin resistance (IR), and external factors are considered to play a key role in this process. Special attention should be paid to MS in young patients, who may present the first manifestation of inherited lipodystrophy. The study describes the first known family in Russia (three clinical cases) with familial partial lipodystrophy (FPLD) type 3 caused by heterozygous p.R212Q PPARG mutation (MIM#601487). The study reports rare forms of inherited IR, such as FPLD, and contributes to a better understanding of common disorders such as MS.

1. The IDF consensus worldwide definition of the metabolic syndrome. International diabetes federation, 2006. Available from: http://www.idf.org/webdata/docs/IDF_Meta_def_final.pdf.

2. Соркина Е.Л., Калашникова М.Ф., Мельниченко Г.А., Тюльпаков А.Н. Семейная парциальная липодистрофия (синдром Dunnigan) вследствие мутации в гене LMNA: первое описание клинического случая в России. // Терапевтический архив. – 2015. – Т. 87. – №3 – С.83-87. [Sorkina EL, Kalashnikova MF, Melnichenko GA, Tyulpakov AN. Familial partial lipodystrophy (Dunnigan syndrome) due to LMNA gene mutation: The first description of its clinical case in Russia (Article in Russian). Ter Arkh. 2015;87(3):83-87.] doi: 10.17116/terarkh201587383-87

3. Monajemi H, Stroes E, Hegele RA, et al. Inherited lipodystrophies and the metabolic syndrome. Clin Endocrinol (Oxf). 2007;67(4):479-484. doi: 10.1111/j.1365-2265.2007.02906.x

4. Monajemi H, Zhang L, Li G, et al. Familial partial lipodystrophy phenotype resulting from a single-base mutation in deoxyribonucleic acid-binding domain of peroxisome proliferator-activated receptor-gamma. J Clin Endocrinol Metab. 2007;92(5):1606-1612. doi: 10.1210/jc.2006-1807

5. den Dunnen JT, Antonarakis SE. Nomenclature for the description of human sequence variations. Hum Genet. 2001;109(1):121-4. 121-124. doi: 10.1007/s004390100505

6. Fiorenza CG, Chou SH, Mantzoros CS. Lipodystrophy: pathophysiology and advances in treatment. Nat Rev Endocrinol. 2011;7(3):137-150. doi: 10.1038/nrendo.2010.199

7. Rother KI, Brown RJ. Novel forms of lipodystrophy: why should we care? Diabetes Care. 2013;36(8):2142-2145. doi: 10.2337/dc13-0561

8. Rosen ED, Sarraf P, Troy AE, et al. PPARγ Is Required for the Differentiation of Adipose Tissue In Vivo and In Vitro. Mol Cell. 1999;4(4):611-617. doi:10.1016/s1097-2765(00)80211-7

9. Barroso I, Gurnell M, Crowley VE, et al. Dominant negative mutations in human PPAR-gamma associated with severe insulin resistance, diabetes mellitus and hypertension. Nature. 1999;402(6764):880-883. doi:10.1038/47254

10. Savage DB, Tan GD, Acerini CL, et al. Human metabolic syndrome resulting from dominant-negative mutations in the nuclear receptor peroxisome proliferator-activated receptor-gamma. Diabetes. 2003;52(4):910-917. doi: 10.2337/diabetes.52.4.910

11. Visser ME, Kropman E, Kranendonk ME, et al. Characterisation of non-obese diabetic patients with marked insulin resistance identifies a novel familial partial lipodystrophy-associated PPARγ mutation (Y151C). Diabetologia. 2011;54(7):1639-1644. doi: 10.1007/s00125-011-2142-4

12. Hegele RA, Cao H, Frankowski C, et al. PPARG F388L, a transactivation-deficient mutant, in familial partial lipodystrophy. Diabetes. 2002;51(12):3586-3590. doi:10.2337/diabetes.51.12.3586

13. Agarwal AK, Garg A. A novel heterozygous mutation in peroxisome proliferator-activated receptor-gamma gene in a patient with familial partial lipodystrophy. J Clin Endocrinol Metab. 2002;87(1):408-411. doi:10.1210/jcem.87.1.8290

14. Francis GA, Li G, Casey R, et al. Peroxisomal proliferator activated receptor-γ deficiency in a Canadian kindred with familial partial lipodystrophy type 3 (FPLD3). BMC Med Genet. 2006;7:3. doi:10.1186/1471-2350-7-3

15. Lüdtke A, Buettner J, Wu W, et al. Peroxisome proliferator-activated receptor-gamma C190S mutation causes partial lipodystrophy. J Clin Endocrinol Metab. 2007;92(6):2248-2255. doi: 10.1210/jc.2005-2624